Jade Biosciences appointed Dr. Mark Eisner, M.D., M.P.H., as a Class I director effective June 25, 2026. Dr. Eisner will serve on the Nominating and Corporate Governance Committee. The appointment includes a stock option grant for 47,675 shares, vesting in equal monthly installments over three years. Dr. Eisner brings extensive experience from leadership roles at Vir Biotechnology, Sonoma Biotherapeutics, FibroGen, and Genentech/Roche.